Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK

Stephen M. Beard, L. McCrink, T. K. Le, A. Garcia-Cebrian, B. Monz, Rayaz Malik

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: The objective of this analysis was to evaluate the cost-effectiveness of duloxetine when considered as an additional treatment option for UK-based patients suffering from diabetic peripheral neuropathic pain. Research design and methods: A decision-analytic model was used to represent the sequential management of patients with diabetic peripheral neuropathic pain. The standard UK treatment strategy was defined as first-line tricyclic antidepressants (amitriptyline), second-line anticonvulsants (gabapentin) and lastly an opioid-related treatment. The cost-effectiveness of duloxetine was evaluated as an additional first, second, third or fourth-line therapy over a 6-month treatment period for a cohort of 1000 patients. Treatment response was modelled based on changes from baseline pain severity using a standard 11-point pain scale (0-10); full response (≥ 50% change), partial response (30-49%) and no response (< 30%). The model was populated with efficacy and discontinuation data using indirect comparisons of treatment efficacy based on relative effects to a common placebo comparator. Results: The second-line use of duloxetine resulted in cost savings of £77071 for every 1000 treated patients, with an additional 29 patients achieving a full pain response when compared to standard UK treatment. Additional quality-adjusted life years (QALYs) were achieved at 1.88 QALYs per 1000 patients. Conclusions: This UK-based economic model suggests that second-line use of duloxetine is a beneficial and cost-effective treatment strategy for diabetic peripheral neuropathic pain.

Original languageEnglish
Pages (from-to)385-399
Number of pages15
JournalCurrent Medical Research and Opinion
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 2008
Externally publishedYes

Fingerprint

Neuralgia
Cost-Benefit Analysis
Quality-Adjusted Life Years
Pain
Therapeutics
Economic Models
Amitriptyline
Cost Savings
Tricyclic Antidepressive Agents
Duloxetine Hydrochloride
Health Care Costs
Anticonvulsants
Opioid Analgesics
Research Design
Placebos

Keywords

  • Cost-effectiveness
  • Diabetes
  • Duloxetine
  • Economic evaluation
  • Neuropathic pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. / Beard, Stephen M.; McCrink, L.; Le, T. K.; Garcia-Cebrian, A.; Monz, B.; Malik, Rayaz.

In: Current Medical Research and Opinion, Vol. 24, No. 2, 02.2008, p. 385-399.

Research output: Contribution to journalArticle

Beard, Stephen M. ; McCrink, L. ; Le, T. K. ; Garcia-Cebrian, A. ; Monz, B. ; Malik, Rayaz. / Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. In: Current Medical Research and Opinion. 2008 ; Vol. 24, No. 2. pp. 385-399.
@article{7af8af77975642fd9e73f239c95b0831,
title = "Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK",
abstract = "Objective: The objective of this analysis was to evaluate the cost-effectiveness of duloxetine when considered as an additional treatment option for UK-based patients suffering from diabetic peripheral neuropathic pain. Research design and methods: A decision-analytic model was used to represent the sequential management of patients with diabetic peripheral neuropathic pain. The standard UK treatment strategy was defined as first-line tricyclic antidepressants (amitriptyline), second-line anticonvulsants (gabapentin) and lastly an opioid-related treatment. The cost-effectiveness of duloxetine was evaluated as an additional first, second, third or fourth-line therapy over a 6-month treatment period for a cohort of 1000 patients. Treatment response was modelled based on changes from baseline pain severity using a standard 11-point pain scale (0-10); full response (≥ 50{\%} change), partial response (30-49{\%}) and no response (< 30{\%}). The model was populated with efficacy and discontinuation data using indirect comparisons of treatment efficacy based on relative effects to a common placebo comparator. Results: The second-line use of duloxetine resulted in cost savings of £77071 for every 1000 treated patients, with an additional 29 patients achieving a full pain response when compared to standard UK treatment. Additional quality-adjusted life years (QALYs) were achieved at 1.88 QALYs per 1000 patients. Conclusions: This UK-based economic model suggests that second-line use of duloxetine is a beneficial and cost-effective treatment strategy for diabetic peripheral neuropathic pain.",
keywords = "Cost-effectiveness, Diabetes, Duloxetine, Economic evaluation, Neuropathic pain",
author = "Beard, {Stephen M.} and L. McCrink and Le, {T. K.} and A. Garcia-Cebrian and B. Monz and Rayaz Malik",
year = "2008",
month = "2",
doi = "10.1185/030079908X253852",
language = "English",
volume = "24",
pages = "385--399",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK

AU - Beard, Stephen M.

AU - McCrink, L.

AU - Le, T. K.

AU - Garcia-Cebrian, A.

AU - Monz, B.

AU - Malik, Rayaz

PY - 2008/2

Y1 - 2008/2

N2 - Objective: The objective of this analysis was to evaluate the cost-effectiveness of duloxetine when considered as an additional treatment option for UK-based patients suffering from diabetic peripheral neuropathic pain. Research design and methods: A decision-analytic model was used to represent the sequential management of patients with diabetic peripheral neuropathic pain. The standard UK treatment strategy was defined as first-line tricyclic antidepressants (amitriptyline), second-line anticonvulsants (gabapentin) and lastly an opioid-related treatment. The cost-effectiveness of duloxetine was evaluated as an additional first, second, third or fourth-line therapy over a 6-month treatment period for a cohort of 1000 patients. Treatment response was modelled based on changes from baseline pain severity using a standard 11-point pain scale (0-10); full response (≥ 50% change), partial response (30-49%) and no response (< 30%). The model was populated with efficacy and discontinuation data using indirect comparisons of treatment efficacy based on relative effects to a common placebo comparator. Results: The second-line use of duloxetine resulted in cost savings of £77071 for every 1000 treated patients, with an additional 29 patients achieving a full pain response when compared to standard UK treatment. Additional quality-adjusted life years (QALYs) were achieved at 1.88 QALYs per 1000 patients. Conclusions: This UK-based economic model suggests that second-line use of duloxetine is a beneficial and cost-effective treatment strategy for diabetic peripheral neuropathic pain.

AB - Objective: The objective of this analysis was to evaluate the cost-effectiveness of duloxetine when considered as an additional treatment option for UK-based patients suffering from diabetic peripheral neuropathic pain. Research design and methods: A decision-analytic model was used to represent the sequential management of patients with diabetic peripheral neuropathic pain. The standard UK treatment strategy was defined as first-line tricyclic antidepressants (amitriptyline), second-line anticonvulsants (gabapentin) and lastly an opioid-related treatment. The cost-effectiveness of duloxetine was evaluated as an additional first, second, third or fourth-line therapy over a 6-month treatment period for a cohort of 1000 patients. Treatment response was modelled based on changes from baseline pain severity using a standard 11-point pain scale (0-10); full response (≥ 50% change), partial response (30-49%) and no response (< 30%). The model was populated with efficacy and discontinuation data using indirect comparisons of treatment efficacy based on relative effects to a common placebo comparator. Results: The second-line use of duloxetine resulted in cost savings of £77071 for every 1000 treated patients, with an additional 29 patients achieving a full pain response when compared to standard UK treatment. Additional quality-adjusted life years (QALYs) were achieved at 1.88 QALYs per 1000 patients. Conclusions: This UK-based economic model suggests that second-line use of duloxetine is a beneficial and cost-effective treatment strategy for diabetic peripheral neuropathic pain.

KW - Cost-effectiveness

KW - Diabetes

KW - Duloxetine

KW - Economic evaluation

KW - Neuropathic pain

UR - http://www.scopus.com/inward/record.url?scp=39749104685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749104685&partnerID=8YFLogxK

U2 - 10.1185/030079908X253852

DO - 10.1185/030079908X253852

M3 - Article

VL - 24

SP - 385

EP - 399

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 2

ER -